Silica nanorings, methods of making silica nanorings, and uses of silica nanorings. The silica nanorings may be surface selective functionalization, with one or more polyethylene glycol (PEG) group(s), one or more display group(s), one or more functional group(s), or a combination thereof. The silica nanorings may have a size of 5 to 20 nm. The silica nanorings may be made using micelles. The absence or presence of the micelles during PEGylation and/or functionalization allows for the surface selective functionalization. The silica nanorings may be used in various diagnostic and/or treatment methods.

Silica nanorings, methods of making silica nanorings, and uses of silica nanorings. The silica nanorings may be surface selective functionalization, with one or more polyethylene glycol (PEG) group(s), one or more display group(s), one or more functional group(s), or a combination thereof. The silica nanorings may have a size of 5 to 20 nm. The silica nanorings may be made using micelles. The absence or presence of the micelles during PEGylation and/or functionalization allows for the surface selective functionalization. The silica nanorings may be used in various diagnostic and/or treatment methods.

A glass material that includes: from about 0.55 to about 0.85 mole fraction of SiO.sub.2; from about 0.01 to about 0.23 mole fraction of Na.sub.2O, K.sub.2O, or a combination of Na.sub.2O and K.sub.2O; from about 0.05 to about 0.28 mole fraction of: Y.sub.2O.sub.3, BaO, or a combination of Y.sub.2O.sub.3 and BaO; and optionally Ta.sub.2O.sub.5. In the glass material, the sum of the Y.sub.2O.sub.3, the BaO and the optional Ta.sub.2O.sub.5 is from about 0.10 to about 0.31 mole fraction. The glass material may be in the form of microspheres. The microspheres may be used for vascular embolization and/or radiologic imaging.

Systems and methods of blocking a biological vessel 2 are provided. The systems and methods may comprise introducing to the vessel an amphiphilic peptide. The peptide may comprise at least thirteen amino acids that may alternate between a hydrophobic amino acid and a hydrophilic amino acid. The peptide may form a beta- sheet spontaneously in an aqueous solution in the presence of a cation.

A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier.

A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier.

Provided is a compound including at least one carrier moiety associated with a plurality of CT imaging moieties, and with at least one enzyme interacting moiety as well as uses thereof in diagnosis.

The invention relates to an iodinated CT contrast agent for non-invasive diagnosis of cachexia. This is possible by superior resolution of CT combined with CT contrast agent specific for the brown and/or beige adipose tissue (BAT).

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and/or energy are effective to injury or damage the tissues to have a benefit of symptom relive.

The present disclosure relates to systems and methods for visualizing a guidewire in a roadmap image. In accordance with certain embodiments, a method includes generating a background mask as a function of at least one background image, wherein the at least one background image includes a blood vessel of interest, generating a contrast mask as a function of at least one contrast image, wherein the at least one contrast image includes a contrast within the blood vessel of interest, receiving a guidewire image, wherein the guidewire image includes a guidewire within the blood vessel of interest, generating a roadmap image as a function of the background mask, contrast mask, and guidewire image, wherein the roadmap image includes the blood vessel of interest, and the guidewire, and outputting the roadmap image to a display.